Oncotelic Therapeutics, Inc. (OTLC)
USD 0.05
(-25.71%)
USD 0.05
(-25.71%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 12.8 Million USD | 16.26% |
| 2022 | 11.01 Million USD | 30.75% |
| 2021 | 8.42 Million USD | 69.99% |
| 2020 | 4.95 Million USD | 249.14% |
| 2019 | 1.41 Million USD | 325.67% |
| 2018 | -629 Thousand USD | 43.59% |
| 2017 | -1.11 Million USD | 68.46% |
| 2016 | -3.53 Million USD | 87.04% |
| 2015 | -27.28 Million USD | 9.14% |
| 2014 | -30.03 Million USD | -328.71% |
| 2013 | -7 Million USD | -41.06% |
| 2012 | -4.96 Million USD | 50.3% |
| 2011 | -9.99 Million USD | -117.12% |
| 2010 | -4.6 Million USD | 66.97% |
| 2009 | -13.93 Million USD | 23.76% |
| 2008 | -18.27 Million USD | -114.32% |
| 2007 | -8.52 Million USD | 45.64% |
| 2006 | -15.68 Million USD | 51.5% |
| 2005 | -32.34 Million USD | -102.3% |
| 2004 | -15.98 Million USD | -2111.34% |
| 2003 | -723 Thousand USD | 80.73% |
| 2002 | -3.75 Million USD | 79.52% |
| 2001 | -18.31 Million USD | 32.31% |
| 2000 | -27.06 Million USD | 8.25% |
| 1999 | -29.49 Million USD | 7.24% |
| 1998 | -31.8 Million USD | 20.7% |
| 1997 | -40.1 Million USD | 0.99% |
| 1996 | -40.5 Million USD | -289.42% |
| 1995 | -10.4 Million USD | -766.67% |
| 1994 | -1.2 Million USD | 84.0% |
| 1993 | -7.5 Million USD | -3650.0% |
| 1992 | -200 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 13.1 Million USD | 2.34% |
| 2024 Q2 | 12.9 Million USD | -4.38% |
| 2023 Q1 | 11.66 Million USD | 5.94% |
| 2023 FY | 12.8 Million USD | 16.26% |
| 2023 Q4 | 12.8 Million USD | 5.71% |
| 2023 Q3 | 12.11 Million USD | 1.37% |
| 2023 Q2 | 11.95 Million USD | 2.42% |
| 2022 Q1 | 10.2 Million USD | 21.11% |
| 2022 Q4 | 11.01 Million USD | 12.09% |
| 2022 FY | 11.01 Million USD | 30.75% |
| 2022 Q2 | 9.4 Million USD | -7.85% |
| 2022 Q3 | 9.82 Million USD | 4.52% |
| 2021 Q2 | 6.56 Million USD | 17.04% |
| 2021 Q1 | 5.61 Million USD | 13.22% |
| 2021 FY | 8.42 Million USD | 69.99% |
| 2021 Q3 | 7.26 Million USD | 10.63% |
| 2021 Q4 | 8.42 Million USD | 15.96% |
| 2020 Q4 | 4.95 Million USD | 198.53% |
| 2020 Q1 | 2.71 Million USD | 90.93% |
| 2020 Q2 | 1.81 Million USD | -33.19% |
| 2020 Q3 | 1.66 Million USD | -8.32% |
| 2020 FY | 4.95 Million USD | 249.14% |
| 2019 Q3 | 472.13 Thousand USD | 228.66% |
| 2019 Q2 | 143.65 Thousand USD | 199.07% |
| 2019 FY | 1.41 Million USD | 325.67% |
| 2019 Q4 | 1.41 Million USD | 200.65% |
| 2019 Q1 | -145 Thousand USD | 76.95% |
| 2018 FY | -629 Thousand USD | 43.59% |
| 2018 Q3 | -1.05 Million USD | 46.19% |
| 2018 Q4 | -629 Thousand USD | 40.55% |
| 2018 Q1 | -233 Thousand USD | 79.1% |
| 2018 Q2 | -1.96 Million USD | -743.78% |
| 2017 Q4 | -1.11 Million USD | 41.56% |
| 2017 FY | -1.11 Million USD | 68.46% |
| 2017 Q1 | -6.04 Million USD | -70.89% |
| 2017 Q2 | -5 Million USD | 17.17% |
| 2017 Q3 | -1.9 Million USD | 61.87% |
| 2016 Q3 | -5.16 Million USD | 34.92% |
| 2016 Q2 | -7.93 Million USD | 22.74% |
| 2016 FY | -3.53 Million USD | 87.04% |
| 2016 Q4 | -3.53 Million USD | 31.59% |
| 2016 Q1 | -10.27 Million USD | 62.34% |
| 2015 FY | -27.28 Million USD | 9.14% |
| 2015 Q3 | -30.25 Million USD | 8.59% |
| 2015 Q4 | -27.28 Million USD | 9.8% |
| 2015 Q1 | -35.73 Million USD | -18.99% |
| 2015 Q2 | -33.09 Million USD | 7.39% |
| 2014 Q3 | -32.88 Million USD | 9.33% |
| 2014 Q4 | -30.03 Million USD | 8.68% |
| 2014 Q2 | -36.27 Million USD | -46.64% |
| 2014 Q1 | -24.73 Million USD | -253.1% |
| 2014 FY | -30.03 Million USD | -328.71% |
| 2013 FY | -7 Million USD | -41.06% |
| 2013 Q4 | -7 Million USD | 20.37% |
| 2013 Q1 | -4.58 Million USD | 7.36% |
| 2013 Q2 | -7.75 Million USD | -69.18% |
| 2013 Q3 | -8.79 Million USD | -13.48% |
| 2012 FY | -4.96 Million USD | 50.3% |
| 2012 Q3 | -6.32 Million USD | 8.65% |
| 2012 Q4 | -4.94 Million USD | 21.78% |
| 2012 Q1 | -8.14 Million USD | 18.31% |
| 2012 Q2 | -6.92 Million USD | 15.03% |
| 2011 FY | -9.99 Million USD | -117.12% |
| 2011 Q4 | -9.97 Million USD | 21.26% |
| 2011 Q3 | -12.66 Million USD | -49.69% |
| 2011 Q2 | -8.46 Million USD | -212.75% |
| 2011 Q1 | -2.7 Million USD | 41.22% |
| 2010 FY | -4.6 Million USD | 66.97% |
| 2010 Q1 | -14.01 Million USD | -0.59% |
| 2010 Q2 | -7.23 Million USD | 48.36% |
| 2010 Q3 | -6.45 Million USD | 10.82% |
| 2010 Q4 | -4.6 Million USD | 28.7% |
| 2009 Q2 | -8.04 Million USD | 34.16% |
| 2009 Q1 | -12.21 Million USD | 33.14% |
| 2009 Q3 | -21.88 Million USD | -172.01% |
| 2009 Q4 | -13.93 Million USD | 36.33% |
| 2009 FY | -13.93 Million USD | 23.76% |
| 2008 Q4 | -18.27 Million USD | -108.74% |
| 2008 FY | -18.27 Million USD | -114.32% |
| 2008 Q1 | -11.49 Million USD | -34.77% |
| 2008 Q3 | -8.75 Million USD | 40.37% |
| 2008 Q2 | -14.68 Million USD | -27.76% |
| 2007 Q1 | -21.87 Million USD | -39.45% |
| 2007 FY | -8.52 Million USD | 45.64% |
| 2007 Q2 | -9.37 Million USD | 57.15% |
| 2007 Q3 | -11.82 Million USD | -26.19% |
| 2007 Q4 | -8.52 Million USD | 27.91% |
| 2006 Q4 | -15.68 Million USD | 22.38% |
| 2006 Q1 | -26.66 Million USD | 17.56% |
| 2006 Q2 | -25.7 Million USD | 3.58% |
| 2006 FY | -15.68 Million USD | 51.5% |
| 2006 Q3 | -20.21 Million USD | 21.39% |
| 2005 Q4 | -32.34 Million USD | -141.77% |
| 2005 Q3 | -13.37 Million USD | 37.33% |
| 2005 Q2 | -21.34 Million USD | 36.77% |
| 2005 Q1 | -33.76 Million USD | -111.18% |
| 2005 FY | -32.34 Million USD | -102.3% |
| 2004 Q3 | -13.41 Million USD | -30.44% |
| 2004 FY | -15.98 Million USD | -2111.34% |
| 2004 Q1 | -13.65 Million USD | -1788.66% |
| 2004 Q2 | -10.28 Million USD | 24.69% |
| 2004 Q4 | -15.98 Million USD | -19.19% |
| 2003 FY | -723 Thousand USD | 80.73% |
| 2003 Q4 | -723 Thousand USD | 75.18% |
| 2003 Q3 | -2.91 Million USD | 74.98% |
| 2003 Q2 | -11.64 Million USD | -591.39% |
| 2003 Q1 | -1.68 Million USD | 55.12% |
| 2002 Q1 | -16.52 Million USD | 9.79% |
| 2002 Q3 | -5.88 Million USD | 42.45% |
| 2002 Q2 | -10.22 Million USD | 38.15% |
| 2002 FY | -3.75 Million USD | 79.52% |
| 2002 Q4 | -3.75 Million USD | 36.21% |
| 2001 Q2 | -22.8 Million USD | 7.03% |
| 2001 FY | -18.31 Million USD | 32.31% |
| 2001 Q4 | -18.31 Million USD | 11.72% |
| 2001 Q1 | -24.52 Million USD | 9.38% |
| 2001 Q3 | -20.74 Million USD | 9.0% |
| 2000 Q1 | -37.48 Million USD | -27.07% |
| 2000 Q3 | -28.43 Million USD | 6.28% |
| 2000 Q4 | -27.06 Million USD | 4.82% |
| 2000 Q2 | -30.34 Million USD | 19.05% |
| 2000 FY | -27.06 Million USD | 8.25% |
| 1999 FY | -29.49 Million USD | 7.24% |
| 1999 Q1 | -29.9 Million USD | 5.97% |
| 1999 Q2 | -27.5 Million USD | 8.03% |
| 1999 Q3 | -23.8 Million USD | 13.45% |
| 1999 Q4 | -29.49 Million USD | -23.93% |
| 1998 Q3 | -34.8 Million USD | 4.13% |
| 1998 FY | -31.8 Million USD | 20.7% |
| 1998 Q1 | -38.6 Million USD | 3.74% |
| 1998 Q2 | -36.3 Million USD | 5.96% |
| 1998 Q4 | -31.8 Million USD | 8.62% |
| 1997 FY | -40.1 Million USD | 0.99% |
| 1997 Q2 | -42.2 Million USD | 1.17% |
| 1997 Q4 | -40.1 Million USD | 4.98% |
| 1997 Q3 | -42.2 Million USD | 0.0% |
| 1997 Q1 | -42.7 Million USD | -5.43% |
| 1996 Q4 | -40.5 Million USD | -226.61% |
| 1996 Q3 | -12.4 Million USD | -15.89% |
| 1996 FY | -40.5 Million USD | -289.42% |
| 1996 Q2 | -10.7 Million USD | -1.9% |
| 1996 Q1 | -10.5 Million USD | -0.96% |
| 1995 Q2 | -300 Thousand USD | 40.0% |
| 1995 Q1 | -500 Thousand USD | 58.33% |
| 1995 Q4 | -10.4 Million USD | 0.0% |
| 1995 FY | -10.4 Million USD | -766.67% |
| 1994 Q2 | -2.5 Million USD | 0.0% |
| 1994 Q4 | -1.2 Million USD | 0.0% |
| 1994 FY | -1.2 Million USD | 84.0% |
| 1993 Q3 | -7.4 Million USD | 0.0% |
| 1993 FY | -7.5 Million USD | -3650.0% |
| 1993 Q4 | -7.5 Million USD | -1.35% |
| 1992 FY | -200 Thousand USD | 0.0% |
| 1992 Q4 | -200 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 977702.29% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -126.731% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 70.073% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 5230.434% |
| Rebus Holdings, Inc. | 305 Thousand USD | -4098.882% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 303.133% |
| Qrons Inc. | 351.42 Thousand USD | -3544.168% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -1957.733% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 70.515% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 62852.793% |
| Skye Bioscience, Inc. | -5.72 Million USD | 323.837% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 18.755% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -210.989% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -3086.916% |
| SQZ Biotechnologies Company | -36.23 Million USD | 135.34% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -471.153% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -1281.232% |
| Mesoblast Limited | 55.85 Million USD | 77.073% |
| Marizyme, Inc. | 18.56 Million USD | 31.033% |
| Genus plc | 190.6 Million USD | 93.281% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -472.789% |
| Pharming Group N.V. | 109.8 Million USD | 88.337% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -1388.721% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -955.006% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -1783.322% |
| ContraFect Corporation | -6.02 Million USD | 312.522% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -9411.798% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -1008.384% |
| IMV Inc. | 7.67 Million USD | -66.959% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -132.767% |
| MultiCell Technologies, Inc. | 90.04 USD | -14223123.012% |
| ONE Bio Corp. | 9.04 Million USD | -41.665% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 1844.819% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 1.077% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -836.174% |
| Q BioMed Inc. | 4.06 Million USD | -215.433% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 58.085% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -1170.853% |
| Biomind Labs Inc. | 711.4 Thousand USD | -1700.19% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 78.848% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -540.524% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -3460.254% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -9060.389% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -64361.62% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -481.594% |
| GB Sciences, Inc. | 1.74 Million USD | -632.929% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 7068.132% |
| HST Global, Inc. | 96.79 Thousand USD | -13130.905% |
| CSL Limited | 10.52 Billion USD | 99.878% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -6110.249% |
| Halberd Corporation | 144.72 Thousand USD | -8749.158% |
| Enzolytics Inc. | 981.65 Thousand USD | -1204.59% |
| Agentix Corp. | 37.63 Thousand USD | -33932.021% |
| Resverlogix Corp. | 6.45 Million USD | -98.521% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 2002.659% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.631% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 127.241% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -81.115% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -372.81% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 244.872% |
| AVAX Technologies, Inc. | -5.9 Million USD | 316.943% |
| Zenith Capital Corp. | 10.06 Thousand USD | -127151.49% |
| Genscript Biotech Corporation | -1.06 Billion USD | 101.207% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -6289.494% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -436.731% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -7684.735% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 70012.6% |
| Kadimastem Ltd | -253.1 Thousand USD | 5159.853% |
| Helix BioMedix, Inc. | -2.57 Million USD | 598.305% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 36.839% |
| BioStem Technologies, Inc. | 4.47 Million USD | -186.372% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -6263.397% |
| LadRx Corporation | -2.03 Million USD | 728.863% |
| Cell Source, Inc. | 9.23 Million USD | -38.72% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1916.256% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1916.256% |
| NovAccess Global Inc. | 2.17 Million USD | -487.872% |
| Affymax, Inc. | -5.59 Million USD | 328.812% |
| Itoco Inc. | 228.3 Thousand USD | -5509.422% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -9317.372% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -158.354% |
| Mobile Lads Corp. | 484.23 Thousand USD | -2544.722% |
| CytoDyn Inc. | 20.26 Million USD | 36.795% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 1979480.216% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 138275.66% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -66.19% |
| SYBLEU INC | 473.71 Thousand USD | -2603.443% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -187.335% |
| International Stem Cell Corporation | 2.59 Million USD | -394.463% |
| Bioxytran, Inc. | 1.89 Million USD | -574.417% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -20419.107% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -487.216% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -272.935% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -49.732% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -1557.581% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 1124.527% |
| Neutra Corp. | 52.18 Thousand USD | -24439.809% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 614.528% |
| PureTech Health plc | -167.19 Million USD | 107.66% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 5329.143% |
| IXICO plc | -4.44 Million USD | 388.139% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 3.12% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 76.652% |
| CSL Limited | 10.52 Billion USD | 99.878% |
| Cellectis S.A. | -43.81 Million USD | 129.226% |